Drug intelligence / Profile preview

KACM001

Development stage: Unknown
Lead developer: Beijing Biohealthcare Biotechnology
Modality: Cell Therapies
Administration: Intravenous

Overview

KACM001 is an autologous cell therapy developed by Beijing Biohealthcare Biotechnology Co., Ltd. using its proprietary MTCA-CTL (Multi-Target Antigen-specific Cytotoxic T Lymphocyte) platform. The therapy involves the expansion and activation of a patient's own cytotoxic lymphocytes to target and eliminate tumor cells. It is primarily being investigated for the treatment of locally advanced unresectable or metastatic gastric cancer. Clinical data presented at the 2023 ASCO Annual Meeting indicated a favorable safety profile and promising efficacy. It is currently being evaluated in Phase II clinical trials, often in combination with chemotherapy regimens like S-1/oxaliplatin or cisplatin.

Other names: autologous lymphocyte injectionMTCA-CTL

Beyond the preview

Go deeper on KACM001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KACM001.

Explore the full profile